Gyre Therapeutics has reported its financial results for the fourth quarter and full year 2025, along with providing a business update. The company's full-year 2025 revenue increased by 10% year-over-year to $116.6 million, falling within the revised guidance range. Looking ahead, the company has given revenue guidance for full year 2026 in the range of $100.5 to $111.0 million, representing a potential decline compared to 2025.
For the three months ended December 31, 2025, the company reported revenues of $37.2 million, marking a 33.3% year-over-year increase from the same period in 2024. The growth was primarily driven by increased sales of its products, including Etuary®, Etorel®, and Contiva®.
In terms of expenses, Gyre Therapeutics saw an increase in various operating costs. Selling and marketing expenses for the same period were $23.8 million, representing a 40.8% year-over-year increase. Research and development expenses were $4.8 million, compared to $3.7 million for the same period in 2024. General and administrative expenses also rose to $6.7 million from $5.5 million for the same period in 2024.
The company's income from operations for the three months ended December 31, 2025, was $0.1 million, marking a decrease from $0.7 million for the same period in 2024. The net loss for the period was $1.4 million, compared to a net income of $0.6 million for the same period in 2024. However, the non-GAAP adjusted net income for the same period saw an increase to $4.3 million from $1.1 million in 2024.
For the full year ended December 31, 2025, Gyre Therapeutics reported revenues of $116.6 million, a 10.2% year-over-year increase from 2024. The company highlighted that sales of Contiva® and Etorel® were primarily driven by targeted allocation of commercial and marketing resources to support their launches.
In terms of expenses for the full year 2025, the company reported increased costs across various categories, including selling and marketing, research and development, and general and administrative expenses.
Gyre Therapeutics provided financial guidance for the full year 2026, anticipating revenues in the range of $100.5 million to $111.0 million, reflecting a potential decline compared to 2025. The company plans to prioritize regulatory activities in 2026, including preparation for the planned new drug application (NDA) submission of Hydronidone. Additionally, the company expects to moderate promotional activities for Contiva® and Etorel® due to uncertainties associated with the national centralized drug procurement program and evolving market dynamics.
These financial results and guidance point to the company's efforts to navigate through changing market dynamics and regulatory priorities in the upcoming year. Following these announcements, the company's shares moved -0.26%, and are now trading at a price of $7.68. Check out the company's full 8-K submission here.
